Gout patients face price hike as US FDA restricts unapproved colchicine
This article was originally published in SRA
Executive Summary
The US Food and Drug Association has warned manufacturers, marketers and distributors of unapproved single-ingredient colchicine, commonly used to treat gout and familial Mediterranean fever (FMF), to stop distribution of unapproved drugs1.